Dainippon Sumitomo Awakes To The U.S. Market And Buys Sepracor For $2.6 Billion
This article was originally published in PharmAsia News
Executive Summary
With an eye toward U.S. market expansion, Dainippon Sumitomo Pharma will buy Sepracor for $2.6 billion, a deal that gives the Japanese drug maker a portfolio of marketed and pipeline medicines, as well as an experienced regulatory and commercial organization
You may also be interested in...
Japanese Pharma Expects New Deal Model For Next 20 Years - New York Pharma Forum
NEW YORK - When the New York Pharma Forum, a group consisting primarily of Japanese pharmaceutical executives, gathered for its 20th General Assembly, members reflected on their companies' early days in the U.S. and their prospects for the future, when the scope of partnerships between Western pharma and Asia Pacific pharma will begin to change
Japanese Pharma Expects New Deal Model For Next 20 Years - New York Pharma Forum
NEW YORK - When the New York Pharma Forum, a group consisting primarily of Japanese pharmaceutical executives, gathered for its 20th General Assembly, members reflected on their companies' early days in the U.S. and their prospects for the future, when the scope of partnerships between Western pharma and Asia Pacific pharma will begin to change
Japanese Dainippon Sumitomo Pharma To Acquire Sepracor For $2.6 Billion
The share price of Sepracor surged by over 25 percent to a high of $22.80 before trading was halted mid-day on Sept. 2, amid speculation of an imminent takeover by Japan's Dainippon Sumitomo Pharma